Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Metabolic Precision Panel > Glycine Encephalopathy Precision Panel

Glycine Encephalopathy Precision Panel

Glycine encephalopathy, also known as autosomal recessive nonketotic hyperglycinemia is caused by mutations in the genes encoding components of the glycine cleavage system. It is caused by mutations in the glycine transporter 1 (GLYT1).
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Glycine encephalopathy, also known as autosomal recessive nonketotic hyperglycinemia is caused by mutations in the genes encoding components of the glycine cleavage system. It is caused by mutations in the glycine transporter 1 (GLYT1). Glycine encephalopathy an acute metabolic emergency result of an inborn error of metabolism which can result in significant morbidity, progressive neurologic injury, or death. Optimal outcomes of this complication depend upon recognition of the signs and symptoms of metabolic disease, prompt evaluation and referral to a center for evaluation and management. Mutations involved in the glycine cleavage system are inherited in an autosomal recessive pattern.  

  • The Igenomix Glycine Encephalopathy Precision Panel can be used to make an accurate and directed diagnosis ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Glycine Encephalopathy Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations during the newborn period: 
    • Respiratory failure requiring mechanical ventilation 
    • Severe hypotonia progressing to limb hypertonicity 
    • Startle-like responses 
    • Dysmorphic features 
    • Musculoskeletal abnormalities 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of multidisciplinary treatment including paediatricians, neurologists, geneticists, genetic counsellors, dietitians, physiotherapists, occupational therapies and orthopaedic surgeons. Dietary restrictions can help prevent acute flares. 
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation 

Genes & Diseases

Methodology

References

See scientific referrals

Alfallaj, R., & Alfadhel, M. (2019). Glycine Transporter 1 Encephalopathy From Biochemical Pathway to Clinical Disease: Review. Child neurology open, 6, 2329048X19831486. https://doi.org/10.1177/2329048X19831486 

Van Hove, J., Coughlin, C., II, Swanson, M., & Hennermann, J. B. (2002). Nonketotic Hyperglycinemia. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle. 

Swanson, M. A., Coughlin, C. R., Jr, Scharer, G. H., Szerlong, H. J., Bjoraker, K. J., Spector, E. B., Creadon-Swindell, G., Mahieu, V., Matthijs, G., Hennermann, J. B., Applegarth, D. A., Toone, J. R., Tong, S., Williams, K., & Van Hove, J. L. (2015). Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia. Annals of neurology, 78(4), 606–618. https://doi.org/10.1002/ana.24485 

Kurolap, A., Armbruster, A., Hershkovitz, T., Hauf, K., Mory, A., Paperna, T., Hannappel, E., Tal, G., Nijem, Y., Sella, E., Mahajnah, M., Ilivitzki, A., Hershkovitz, D., Ekhilevitch, N., Mandel, H., Eulenburg, V., & Baris, H. N. (2016). Loss of Glycine Transporter 1 Causes a Subtype of Glycine Encephalopathy with Arthrogryposis and Mildly Elevated Cerebrospinal Fluid Glycine. American journal of human genetics, 99(5), 1172–1180. https://doi.org/10.1016/j.ajhg.2016.09.004 

Krawiec, C., & Goyal, A. (2021). Nonketotic Hyperglycinemia. In StatPearls. StatPearls Publishing. 

Poothrikovil, R. P., Al Thihli, K., Al Futaisi, A., & Al Murshidi, F. (2019). Nonketotic Hyperglycinemia: Two Case Reports and Review. The Neurodiagnostic journal, 59(3), 142–151. https://doi.org/10.1080/21646821.2019.1645549 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information